Australia's first evidence-based menopause guidelines: what changed

If you have been told that your hot flushes are “normal,” that there is “nothing you can do,” or — worse — that hormone therapy is too dangerous to even discuss, this week’s news is for you.

Australia’s peak obstetrics and gynaecology college, RANZCOG, has released its first evidence-based clinical guidelines on managing menopausal symptoms. Not a position statement. Not a consensus opinion. Evidence-graded clinical guidelines — the kind that are supposed to end the inconsistency of walking into three different GPs and getting three different answers.

The system did not get menopause right for a long time. Women were told for two decades to avoid hormones — a reading of the Women’s Health Initiative study that turned out to be significantly overstated, or at least wrong for the women most affected by the guidelines it generated: women in their 40s and early 50s who were suffering. That legacy has only been partially corrected in Australian clinical practice, and the clinician variability it produced is exactly what these guidelines are designed to address.

What the guidelines cover — and what they don’t

The RANZCOG guidelines address two clusters of menopausal symptoms:

• Vasomotor symptoms: hot flushes, night sweats
• Genitourinary symptoms: vaginal dryness, urinary frequency, urinary leakage, discomfort during sex

They do not cover bone density, joint pain, libido, depression, or anxiety. That scope is deliberate — the evidence base is strongest for vasomotor and genitourinary symptoms, and a separate government-funded living guideline is expected next year, with RANZCOG contributing.

Knowing what the guidelines don’t cover matters as much as knowing what they do. If your main concern is joint pain, mood, or cognitive symptoms, you are not operating outside the guidance — those symptoms are real, common, and important. They are simply in a separate evidentiary lane.

The evidence picture for treatment

For vasomotor symptoms, MHT remains the best-evidenced treatment in women without contraindications. The guidelines grade this as high-quality evidence. Non-hormonal options — including SSRIs, SNRIs, and oxybutynin — have evidence supporting their use and are appropriate for some women, especially those with contraindications to hormones.

Two findings in the guidelines deserve particular attention.

Exercise and weight loss alone have insufficient evidence to reliably improve hot flushes or night sweats. This matters because it is common practice to tell women to “exercise more and lose weight” as a first-line response to vasomotor symptoms. The evidence base does not support this as a standalone strategy. It is not that exercise is harmful — it is that it should not be the primary recommendation for women who are asking about their hot flushes.

For genitourinary symptoms, local vaginal oestrogen is recommended — including for women with a history of breast cancer. This is a clinically significant clarification. Many women and their oncologists have applied conservative practices around any topical hormones post-breast cancer. The evidence base for local vaginal oestrogen’s safety in this group is stronger than the caution historically applied to it. The conversation with your oncologist and GP is worth having.

Both-and: consistent advice is not the same as right advice for you

The RANZCOG guideline group chair, Catriona Melville, said the aim was to “cut through the noise” with clear, evidence-based recommendations that clinicians can apply consistently. That is legitimate and necessary. GP variability on menopause management has been a documented problem, and women who move cities, change GPs, or see a locum should not receive entirely different advice on the same symptoms.

And: consistent guidelines are not the same as personalised care. Magdalena Simonis, a GP and women’s health researcher at the University of Melbourne, put it well when she said clinicians should treat the whole person, not just the symptom. A woman whose sleep is disrupted by a snoring partner, whose thyroid is running below the reference range, and whose hot flushes started in the same month she began a stressful project — that woman’s experience may have multiple contributing factors. A guideline can identify what is known; a consult personalises it.

The guidelines are a floor, not a ceiling. They define the minimum evidential standard. What happens above that floor is the clinical relationship.

2 cents

What the RANZCOG guidelines mean for your next appointment:

If you have been experiencing hot flushes or night sweats for more than a few months and they are affecting your quality of life, this guideline says your symptoms have a treatment evidence base. Ask your GP what treatment approach they are recommending and what evidence grade supports it. “Exercise more” is not a sufficient first-line answer if your vasomotor symptoms are impacting daily function.

If you have a history of breast cancer and have been told you cannot use any form of oestrogen for genitourinary symptoms: the evidence for topical vaginal oestrogen has shifted in the direction of safety. That conversation with your oncologist is worth initiating.

If you are on MHT and have not had a formal annual review: that review is now explicitly recommended. It is a reasonable request to make.

A government-funded living guideline — broader in scope — is expected in 2027. These RANZCOG guidelines are the available evidence summary today.

Verdict: yes — new, graded, evidence-based guidance that GPs and patients can use now.

---

Sources cited

1. New menopause guidelines designed to cut through misinformation — ABC Health, 17 October 2026
2. RANZCOG Clinical Guidelines — Women’s Health